MiNK Therapeutics, Inc. Operating Cash Flow
MiNK Therapeutics, Inc. (INKT) reported Operating Cash Flow of -$3.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- MiNK Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$2.08M.
- MiNK Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$1.73M.
- MiNK Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$2.07M.
- MiNK Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$941.35K.
- MiNK Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$5.93M.
- MiNK Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$9.56M.
- MiNK Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$15.76M.
- MiNK Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$18.87M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$3.82M 10-Q · filed 2026-08-13 | -$5.89M derived: sum of 3 quarters · filed 2026-08-13 | -$6.83M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$1.73M 10-Q · filed 2026-05-15 | -$3.81M derived: sum of 2 quarters · filed 2026-05-15 | -$4.75M derived: sum of 3 quarters · filed 2026-05-15 | -$6.32M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$3.02M derived: sum of 2 quarters · filed 2026-03-31 | -$4.58M derived: sum of 3 quarters · filed 2026-08-13 | -$5.93M 10-K · filed 2026-03-31 |
| 2025-09-30 | -$941.35K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$2.51M derived: sum of 2 quarters · filed 2026-08-13 | -$3.85M 10-Q · filed 2025-11-14 | -$5.58M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$2.91M 10-Q · filed 2026-08-13 | -$4.64M derived: sum of 3 quarters · filed 2026-08-13 | -$7.63M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$1.34M 10-Q · filed 2026-05-15 | -$3.07M derived: sum of 2 quarters · filed 2026-05-15 | -$6.06M derived: sum of 3 quarters · filed 2026-05-15 | -$8.35M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$4.72M derived: sum of 2 quarters · filed 2026-03-31 | -$7.01M derived: sum of 3 quarters · filed 2026-03-31 | -$9.56M 10-K · filed 2026-03-31 |
| 2024-09-30 | -$2.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$5.29M derived: sum of 2 quarters · filed 2025-11-14 | -$7.83M 10-Q · filed 2025-11-14 | -$10.86M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$2.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$4.83M 10-Q · filed 2025-08-14 | -$7.87M derived: sum of 3 quarters · filed 2025-08-14 | -$12.08M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$2.54M 10-Q · filed 2025-05-15 | -$5.58M derived: sum of 2 quarters · filed 2025-05-15 | -$9.79M derived: sum of 3 quarters · filed 2025-05-15 | -$13.94M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$7.25M derived: sum of 2 quarters · filed 2025-03-18 | -$11.40M derived: sum of 3 quarters · filed 2025-03-18 | -$15.76M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$4.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$8.36M derived: sum of 2 quarters · filed 2024-11-14 | -$12.73M 10-Q · filed 2024-11-14 | -$17.16M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$4.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$8.52M 10-Q · filed 2024-08-13 | -$12.95M derived: sum of 3 quarters · filed 2024-08-13 | -$18.56M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$4.37M 10-Q · filed 2024-05-14 | -$8.80M derived: sum of 2 quarters · filed 2024-05-14 | -$14.41M derived: sum of 3 quarters · filed 2024-05-14 | -$19.04M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$4.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$10.05M derived: sum of 2 quarters · filed 2024-03-21 | -$14.67M derived: sum of 3 quarters · filed 2024-03-21 | -$18.87M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$5.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$10.24M derived: sum of 2 quarters · filed 2023-11-14 | -$14.44M 10-Q · filed 2023-11-14 | -$16.14M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$4.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$8.82M 10-Q · filed 2023-08-10 | -$10.52M derived: sum of 3 quarters · filed 2023-08-10 | -$14.02M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$4.20M 10-Q · filed 2023-05-11 | -$5.90M derived: sum of 2 quarters · filed 2023-05-11 | -$9.39M derived: sum of 3 quarters · filed 2023-05-11 | -$12.81M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$5.20M derived: sum of 2 quarters · filed 2023-03-24 | -$8.62M derived: sum of 3 quarters · filed 2023-03-24 | -$12.83M 10-K · filed 2023-03-24 |
| 2021-09-30 | -$3.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$6.92M derived: sum of 2 quarters · filed 2022-11-03 | -$11.12M 10-Q · filed 2022-11-03 | -$12.84M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$3.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$7.63M 10-Q · filed 2022-08-15 | -$9.35M derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-03-31 | -$4.21M 10-Q · filed 2022-05-13 | -$5.93M derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2020-12-31 | -$1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$8.34M 10-K · filed 2022-03-18 | ||
| 2020-09-30 | -$6.62M 10-Q · filed 2021-11-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |